PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist originally derived from Melanotan II that has been studied extensively for its effects on sexual dysfunction in both men and women. Unlike PDE5 inhibitors, PT-141 acts centrally through the nervous system rather than the vascular system, making it a unique compound in clinical and research settings. Dosing protocols in the literature generally range from 0.5 mg to 2.0 mg administered subcutaneously, with 1.75 mg being the FDA-approved dose for premenopausal women under the brand name Vyleesi.
PT-141 research has expanded significantly since the peptide first emerged from investigations into melanocortin peptides in the early 2000s. As a melanocortin-4 receptor (MC4R) agonist, bremelanotide occupies a distinct pharmacological niche — it modulates desire and arousal through central nervous system pathways rather than acting on peripheral blood flow. This overview examines the mechanism of action, published dosing data, reconstitution protocols, and practical considerations for researchers working with PT-141 in controlled settings.
Mechanism of Action: How PT-141 Works
PT-141 is a cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It functions as a non-selective agonist at melanocortin receptors, with its primary effects attributed to activation of MC4R and, to a lesser extent, MC3R in the hypothalamus and limbic system. These receptors are part of the melanocortin system, which plays a role in regulating sexual behavior, energy homeostasis, and autonomic function.
Unlike sildenafil or tadalafil — which inhibit phosphodiesterase type 5 to increase blood flow to erectile tissue — PT-141 initiates a dopaminergic response in the medial preoptic area of the hypothalamus. This central mechanism is why the compound has demonstrated efficacy in both male and female subjects, addressing arousal and desire at the neurological level rather than solely facilitating a vascular response.
The compound was derived from Melanotan II (MT-II) through targeted structural modification. Researchers removed the linear amino acid extensions of MT-II and created a more targeted cyclic peptide that retained sexual function activity while reducing melanogenic (skin-tanning) side effects, though some residual melanocortin-1 receptor activity remains.
Clinical Research and Published Findings
PT-141 has been the subject of multiple Phase II and Phase III clinical trials. The most significant body of evidence led to FDA approval in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Key findings from the clinical literature include:
In the RECONNECT Phase III trials (two replicate studies totaling approximately 1,247 premenopausal women), bremelanotide 1.75 mg subcutaneous injection demonstrated statistically significant improvements in desire and reductions in distress related to low sexual desire compared to placebo over 24 weeks. The primary endpoints — the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score — both showed meaningful improvement.
Earlier research in male subjects with erectile dysfunction also showed promise. A 2004 study published in the Journal of Urology demonstrated that PT-141 administered intranasally at doses of 7 mg and 20 mg produced erections in men with ED, including a subset of men who had not responded to sildenafil. However, the intranasal route was ultimately abandoned due to concerns about blood pressure elevation, and subcutaneous administration became the standard delivery method in subsequent research.
Dosing Protocols in Research Literature
Dosing for PT-141 varies depending on the administration route, the subject population, and the specific research objectives. The table below summarizes key dosing data from published studies and the approved prescribing information:
| Study / Context | Route | Dose Range | Commonly Used Dose | Timing |
|---|---|---|---|---|
| RECONNECT Phase III (Female HSDD) | Subcutaneous | 1.75 mg | 1.75 mg | ≥45 minutes before anticipated activity |
| Phase II Male ED Trials (Subcutaneous) | Subcutaneous | 0.3 mg – 10 mg | 1.0 – 2.0 mg | 30–60 minutes before assessment |
| Early Intranasal Trials (Male ED) | Intranasal | 7 mg – 20 mg | 10 mg | 30 minutes before assessment |
| Independent Research Protocols | Subcutaneous | 0.5 mg – 2.0 mg | 1.0 mg (starting), 1.75 mg (standard) | 45–60 minutes before observation |
In independent research contexts, many protocols begin with a conservative dose of 0.5 mg to assess individual tolerance before titrating upward to 1.0–1.75 mg. The FDA-approved labeling for Vyleesi specifies no more than one dose per 24-hour period and no more than eight doses per month. These parameters are frequently referenced in research protocols as well.
Peak plasma concentrations are typically reached approximately 30 minutes after subcutaneous injection, with a terminal half-life of roughly 2.7 hours. The onset of subjective effects has been reported within 45 minutes in most clinical observations, with a duration of action extending to approximately 6–8 hours in some subjects.
Reconstitution and Handling
PT-141 is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use. The standard reconstitution vehicle is bacteriostatic water (BAC water), which contains 0.9% benzyl alcohol as a preservative and allows for multiple draws from the same vial over time. Sterile water for injection may also be used but should be consumed in a single session since it lacks a preservative.
A common reconstitution example: adding 1 mL of bacteriostatic water to a 10 mg vial of PT-141 yields a concentration of 10 mg/mL, meaning each 0.1 mL (10 units on a standard insulin syringe) equals 1 mg. Researchers should adjust these calculations based on the vial size and desired concentration.
Once reconstituted, the solution should be stored in a peptide storage case or dedicated mini fridge at 2–8°C (36–46°F). Reconstituted PT-141 generally remains stable for up to 30 days under proper refrigeration, though some conservative protocols recommend use within 14–21 days. Unreconstituted lyophilized powder can be stored at room temperature for short periods, but long-term storage at freezer temperatures (-20°C) is preferred to maintain potency.
What You Will Need
Before beginning this protocol, researchers typically gather the following supplies: bacteriostatic water for reconstitution, insulin syringes for precise measurement (0.5 mL or 1 mL syringes with 29–31 gauge needles are standard for subcutaneous peptide injection), alcohol prep pads for sterile technique at both the vial septum and the injection site, and a sharps container for safe disposal of all used needles and syringes. Proper peptide storage cases or a dedicated mini fridge help maintain compound integrity between uses and are considered essential for any multi-week research protocol.
Side Effect Profile and Safety Considerations
The most commonly reported side effects in clinical trials include nausea (approximately 40% of subjects in the RECONNECT studies), flushing, headache, and injection site reactions. Nausea is the most frequently cited reason for discontinuation and tends to be most pronounced at the first few doses, often attenuating with subsequent administrations. Some researchers report that taking PT-141 with a light meal or alongside ginger supplementation may reduce the incidence of nausea, though this has not been formally studied.
Transient increases in blood pressure have been observed, typically in the range of 2–6 mmHg systolic, resolving within 12 hours. For this reason, PT-141 is contraindicated in individuals with uncontrolled hypertension or significant cardiovascular risk factors. Focal hyperpigmentation (darkening of skin, particularly in the facial and gingival areas) has been noted with repeated dosing, attributed to residual MC1R agonism.
Researchers focused on optimizing recovery and mitigating stress responses during multi-compound protocols often incorporate ashwagandha for its well-documented effects on cortisol modulation and stress resilience. Additionally, magnesium glycinate taken in the evening may support sleep quality and relaxation, which can be relevant since some subjects report mild insomnia or restlessness on dosing days.
Track your peptide protocol for free
Log every dose, cost, weight change, and observation in one place. Free web app — no credit card needed.
Complementary Research Tools and Supplements
Researchers conducting longer-term PT-141 protocols often incorporate complementary tools to support overall physiological health. Omega-3 fish oil supplementation is widely studied for its role in managing systemic inflammation and may support cardiovascular health — a relevant consideration given PT-141’s mild hemodynamic effects. Vitamin D3 is another commonly stacked supplement in research settings, particularly for subjects with suboptimal levels, as adequate vitamin D status supports immune function, mood regulation, and hormonal balance. For researchers exploring multi-peptide stacks or broader longevity protocols, NMN or NAD+ precursors have attracted significant interest for their potential role in cellular energy metabolism and mitochondrial health, and may serve as useful adjuncts in comprehensive research frameworks.
Where to Source
When sourcing PT-141 for research purposes, purity verification is non-negotiable. Researchers should prioritize vendors that provide third-party testing results and certificates of analysis (COAs) confirming peptide identity, purity (≥98% by HPLC), and absence of contaminants such as endotoxins or heavy metals. EZ Peptides (ezpeptides.com) is a reputable source that provides third-party COAs with each product and has established a track record among independent peptide researchers. Use code PEPSTACK for 10% off at EZ Peptides. Regardless of vendor, always review the COA before beginning any protocol and verify that the testing was conducted by an independent laboratory.
Frequently Asked Questions
Q: How does PT-141 differ from Melanotan II?
A: PT-141 (bremelanotide) is a cyclic heptapeptide derived from Melanotan II but with key structural modifications that reduce melanogenic (skin-tanning) activity while preserving sexual function effects. Melanotan II is a broader melanocortin agonist with more pronounced effects on pigmentation, appetite suppression, and fat metabolism. PT-141 was specifically engineered to be more targeted toward MC3R and MC4R pathways involved in sexual arousal and desire.
Q: How long does PT-141 take to work after subcutaneous injection?
A: Based on published pharmacokinetic data, peak plasma concentration is reached approximately 30 minutes post-injection, with subjective effects typically reported within 45–60 minutes. The FDA-approved labeling recommends administration at least 45 minutes before anticipated activity. Duration of effect varies but generally extends 6–8 hours, with some reports of residual effects lasting up to 12 hours.
Q: Can PT-141 be used alongside PDE5 inhibitors?
A: In the clinical literature, co-administration of PT-141 with PDE5 inhibitors (such as sildenafil or tadalafil) has not been extensively studied, and caution is warranted. Since PT-141 acts centrally and PDE5 inhibitors act peripherally, the mechanisms are distinct, but both can affect blood pressure. Additive hypotensive effects are a theoretical concern. Researchers should consult relevant safety data and a qualified healthcare professional before combining these compounds in any protocol.
Q: Is PT-141 effective in both male and female research subjects?
A: Yes. Clinical data support efficacy in both populations, though the evidentiary basis differs. PT-141 received FDA approval specifically for premenopausal female HSDD based on robust Phase III data. In male subjects, Phase II trials demonstrated pro-erectile effects, though the compound has not received regulatory approval for male sexual dysfunction. The central mechanism of action — targeting melanocortin receptors in the hypothalamus — is relevant to sexual arousal pathways in both sexes.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.